Adoptive Cell Therapy Market The Rapid Growth 2023-2030 : Transformative Innovations in Cellular Therapeutics| Nihon Kohden Corporation, Hoffmann-La Roche Ltd, Braun Melsungen AG, Abbott

Market Overview:

Adoptive cell therapy is an immunotherapy treatment that uses modified cells from a patient's own immune system to target and kill cancer cells. Adoptive cell therapies involve extracting lymphocytes from a patient's blood and modifying them through genetic engineering to increase their specificity and killing ability against cancer cells. These re-engineered cells are then infused back into the patient to produce an anticancer effect.

Market Dynamics:

The adoptive cell therapy market is expected to witness significant growth over the forecast period owing to rising prevalence of cancer across the globe. According to the World Health Organization (WHO), cancer is the second leading cause of death globally, and was responsible for nearly 10 million deaths in 2020. Furthermore, rising adoption of advanced cancer treatment options such as chimeric antigen receptor (CAR) T-cell therapies is also supporting the market growth. CAR T-cell therapies are revolutionizing cancer treatment and have shown unprecedented success in treating hematological malignancies. In addition, increased funding for cancer immunotherapy research and growing clinical trials for adoptive cell therapies to expand their applications are further propelling the market growth.

Get an Exclusive Sample Copy of the Report at: - https://www.coherentmarketinsights.com/insight/request-sample/4957

Market Driver: Increasing prevalence of cancer globally is driving the adoption of cell therapy in cancer treatment

The increasing prevalence of cancer across the world poses a major health challenge. According to the statistics by the WHO, cancer burden has risen to 18.1 million new cases and 9.6 million cancer deaths in 2018. The four most common cancers in 2018 were lung, breast, colon and prostate cancer. The growing cancer cases are majorly attributed to changing lifestyle habits such as smoking, alcohol consumption, poor diet and physical inactivity. Cancer patients are increasingly demanding for novel and advanced treatment options other than conventional therapies like chemotherapy and radiation therapy. Adoptive cell therapy has emerged as one of the most promising cancer treatment approaches. It harnesses the power of a patient's own immune system cells to fight cancer. Promising clinical trial results showing high response rates and survival improvements with cell therapies are driving oncologists and patients to consider it as a viable treatment option. Pharmaceutical companies are aggressively investing in R&D and product development of adoptive cell therapies, encouraged by the growing demand and market potential.

Market Driver: Advancements in CAR T-cell therapy and growing adoption rates in treating hematological malignancies

Chimeric Antigen Receptor (CAR) T-cell therapy is one of the most advanced types of adoptive cell therapy being used in cancer treatment currently. In CAR T-cell therapy, a patient's T cells are genetically modified to express chimeric antigen receptors (CARs) targeting specific tumor antigens. Two CAR T-cell therapies Kymriah by Novartis and Yescarta by Gilead Sciences have been approved by the FDA to treat certain types of lymphoma and leukemia. The approvals were based on high overall response rates exceeding 80% observed in pivotal clinical trials. Driven by the significant clinical efficacy demonstrated, CAR T-cell therapy adoption is continuously rising in treating hematological malignancies like acute lymphoblastic leukemia and lymphoma. This is a major driver behind the growth of the adoptive cell therapy market. Ongoing advancements in CAR T research and development for both hematologic and solid tumor indications offer further opportunities to expand the viable patient pool and market potential going forward.

Market Restrain: High Cost of Cell Therapy Development and Treatment

While adoptive cell therapy holds promise in cancer treatment, high costs involved are a major restrain hindering wider market adoption. Development of novel cell therapy products require complex R&D process involving gene isolation and modification, cell culture, characterization and large scale manufacturing which makes it a capital intensive endeavor. Even approved CAR T-cell therapies like Kymriah and Yescarta cost over $373,000 per treatment course to the healthcare systems in the US. The high cost is further augmented in commercialization stage due to capital expenditure on building manufacturing facilities, obtaining regulatory approvals and infrastructure development for large scale production and distribution of living cell products. For healthcare systems and payers, the high cell therapy treatment costs pose economic and budgeting challenges. This factor remains a major consideration for oncologists and patients in choosing cell therapy and also limits broader market access especially in developing countries. Cost reductions through technical advancements, operational efficiencies and development of cheaper alternatives would be crucial to enable wider market adoption.

Market Opportunity: Development of Off-the-Shelf Allogeneic Cell Therapies

While approved CAR T-cell therapies currently follow an autologous approach where a patient's own immune cells are genetically engineered ex-vivo, development of off-the-shelf allogeneic cell therapies offers significant commercial opportunities. Allogeneic cell therapies are manufactured from healthy donor cells in large batches instead of individualized harvesting and engineering. This would address key limitations of autologous approach like manufacturing delays due to individual customization, challenges in scaling production according to patient demand and loss of treatment window due to manufacturing timelines. It will enable 'off-the-shelf' availability of cell therapies eliminating wait times for patients and offer operational efficiencies. Several biotechs are exploring novel manufacturing techniques, developing new allogenic cell lines derived from iPSCs or ESCs with gene editing approaches regulating rejection potential. Success in allogenic cell therapy development will open up lucrative commercial opportunities by addressing the limitations of current autologous CAR T model and enabling wider adoption and accessibility of cell therapies by bringing down manufacturing

List of TOP Players in Market Report are: -

◘ Novartis AG
◘ Gilead Sciences Inc.
◘ Castle Creek Biosciences Inc.
◘ Lineage Cell Therapeutics Inc.
◘ Transgene SA
◘ Cellectis
◘ ImmunityBio Inc.
◘ Sorrento Therapeutics
◘ bluebird bio Inc.
◘ Arcellx
◘ Sana Biotechnology Inc.
◘ Biodesix Inc
◘ Laurus Labs

Note: Major Players are sorted in no particular order.

Market Detailed Segmentation:

By Type :

CAR-T
TCR-T
NK
TIL

By Application :

Lymphoma
Leukemia
Others

By End User :

Hospitals
Cancer Treatment Centers

Buy This Premium Report and Get Upto 25 % OFF: https://www.coherentmarketinsights.com/insight/buy-now/4957

Furthermore, the years considered for the study are as follows:

Historical data - 2016-2021
The base year for estimation - is 2021
Estimated Year - 2023
Forecast period** - 2023 to 2030

This Adoptive Cell Therapy Market Research/Analysis Report Contains Answers to your following Questions:

◈What are the current global trends in the Adoptive Cell Therapy market, and will the market experience an increase or decrease in demand in the upcoming years?

◈ What is the expected demand for various product types within the Adoptive Cell Therapy market, and what are the emerging Market applications and trends?

◈ What are the projections for the global Adoptive Cell Therapy Market in terms of capacity, production, production value, cost, profit, market share, supply, consumption, import, and export?

◈ How will strategic developments shape the Market trajectory in the medium to long term?

◈ What factors contribute to the final price of Adoptive Cell Therapy , and what are the raw materials used in its manufacturing?

◈ What is the market's growth potential, particularly with the increasing adoption of Adoptive Cell Therapy in mining?

◈ What is the current and 2022 value of the global market, and who are the leading companies in this market?

◈ What recent Market trends can be leveraged to create additional revenue streams?

◈ What entry strategies, economic impact mitigation measures, and marketing channels should be considered for the Adoptive Cell Therapy Market?

Summarized Extracts from TOC of Market Study

Chapter 1 Adoptive Cell Therapy Introduction and Market Overview

1.1 Objectives of the Study

1.2 Overview of Adoptive Cell Therapy

1.3 Scope of The Study

1.3.1 Key Market Segments

1.3.2 Players Covered

1.3.3 COVID-19's impact on the Adoptive Cell Therapy industry

1.4 Methodology of The Study

1.5 Research Data Source

Chapter 2 Executive Summary

Chapter 3 Industry Chain Analysis

Chapter 4 Market, by Type

Chapter 5 Market, by Application

Chapter 6 Market Analysis by Regions

Chapter 7 North America Market Analysis by Countries

Chapter 8 Europe Adoptive Cell Therapy Market Analysis by Countries

Chapter 9 Asia Pacific Adoptive Cell Therapy Market Analysis by Countries

Chapter 10 Middle East and Africa Adoptive Cell Therapy Market Analysis by Countries

Chapter 11 South America Adoptive Cell Therapy Market Analysis by Countries

Chapter 12 Competitive Landscape

Chapter 13 Industry Outlook

Chapter 14 Market Forecast

Chapter 15 New Project Feasibility Analysis

Contact Us

Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame,
CA 94010, United States
Phone: US +12067016702 / UK +4402081334027
JAPAN:+81-50-5539-1737
INDIA:+91-848-285-0837
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.